Home
|
About us
|
Contact us
About AWMSG
All Wales Medicines Strategy Group (AWMSG)
New Medicines Group (NMG)
All Wales Prescribing Advisory Group (AWPAG)
Meetings
Appraisals
Appraisal information
Patients/carers/patient organisations
Healthcare professionals
Pharmaceutical industry
Search and reports
Search and browse
Reports
Medicines management
About
Forthcoming work programme
National prescribing indicators
Clinical effectiveness prescribing programme
Appraisal monitoring
In-patient medication administration record
Patient information leaflets
Library
travoprost (Travatan®)
Reference No. 2601
Publication date:
18/11/2015
Appraisal information
travoprost (Travatan®) 40 micrograms/ml eye drops
Company:
Alcon Laboratories (UK) Ltd
BNF category:
Eye
NMG meeting date:
09/09/2015
AWMSG meeting date:
21/10/2015
Submission Type:
Limited Submission
Status:
Recommended
Advice No:
3115
Ratification by Welsh Government:
17/11/2015
Current Progress
Submission
received
NMG
meeting
AWMSG
meeting
Ratification by
Welsh Government
AWMSG advice
Travoprost (Travatan®) is recommended as an option for use within NHS Wales for the decrease of elevated intraocular pressure in paediatric patients aged 2 months to < 18 years with ocular hypertension or paediatric glaucoma.
Final Appraisal Recommendation (FAR)
Download
travoprost (Travatan) 2601 FAR
AWMSG Secretariat Appraisal Report (ASAR)
Download
travoprost (Travatan) 2601 ASAR
Clinical Expert (CE) Summary
Download
travoprost (Travatan) 2601 CE Summary